Standard of care plus telmisartan on respiratory failure due to COVID-19 (STAR-COVID trial)
Description
CONCLUSIONS: Compared with the standard of care, telmisartan therapy demonstrated no significant impact on respiratory failure in hospitalized patients with severe COVID-19.